Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.31 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.31 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020805 | 0.70 | — | — | |
| SCHEMBL4013262 | 0.69 | PTGDR2 (0.32) | PTGDR2KMT2A | |
| SCHEMBL10715229 | 0.68 | PTGDR2 (0.56) | PTGDR2KMT2AALOX15SMN1; SMN2 | |
| SCHEMBL11556832 | 0.66 | ALOX15 (0.50) | PTGDR2KMT2AALOX15SMN1; SMN2 | |
| SCHEMBL21068905 | 0.63 | HRH3 (0.43) | KMT2AALOX15SMN1; SMN2 | |
| SCHEMBL323367 | 0.63 | NR4A2 (0.53) | KMT2A | |
| Hydroquinone SCHEMBL8070696 | 0.63 | CA2 (0.52) | KMT2AALOX15 | |
| SCHEMBL30688439 | 0.62 | MAOA (0.50) | PTGDR2SMN1; SMN2 | |
| SCHEMBL22436349 | 0.62 | MAOA (0.50) | PTGDR2SMN1; SMN2 | |
| SCHEMBL231282 | 0.62 | TSHR (0.61) | KMT2AALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009085040-A1 | PROTEIN KINASE INHIBITORS | DCB-USA LLC (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163494-A1 | PROTEIN KINASE INHIBITORS | BRAF, MAP3K20, SELENOI | PTGDR2 2110/4885KMT2A 1340/4885PTGS1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.